Abstract:Objective To assess the safety of infliximab (IFX) treatment in patients with Crohn's disease(CD).Methods From January 2009 to May 2018,at inflammatory bowel disease (IBD) center of Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,486 CD patients received the treatment of IFX were enrolled and their clinical data were collected.Univariate and multivariate regression of binary logistic were performed for statistical analysis.Results The median follow-up duration was 31.1 months (12.0 months to 40.0 months).The median duration of IFX therapy was 13.0 months (7.0 months to 21.0 months).Among 486 patients,98 (20.16％) patients reported adverse effects,and 12 (2.47％) patients discontinued the therapy because of adverse effects.Acute infusion reaction was the most common adverse effect in CD patients who received IFX treatment accounting for 41.84％ (41/98) of all the adverse effects,and the incidence was 8.44％.Thirty-nine patients had mild and moderate infusion reaction,and all improved after symptomatic treatment (eight patients discontinued IFX therapy because of recurrent infusion reaction).Two patients developed severe infusion reaction as allergic shock,and both relieved after emergency rescue.Four patients developed late-phase allergic reactions.Among 486 patients,39 (8.02％) patients had infections,including infections of Clostridium difficile,cytomegalovirus,herpeszoster virus,Mycobacterium tuberculosis,and other opportunistic pathogens.There was no cases of infection related death.Thirty-six patients continued with IFX treatment after infection controlled.Among 486 patients,14 (2.88％) patients had severe infection,and all the cases improved after anti-infection treatment.Twenty-seven CD patients with hepatitis B virus (HBV) infection received anti-viral treatments,no active HBV infection was observed.Colon adenocarcinoma was found in one patient under colonoscopy at 22 months after discontinuation of IFX therapy.There were six patients with the history of benign tumors,and no evidence of recurrence,progress or malignancy during treatment.In terms of other rare adverse effects in 486 patients,there were eight (1.64％) patients with liver function injury,two (0.41％) patients with anemia,one (0.21％) patient with peripheral neuropathy,and four (0.82％) patients with skin lesion.Prolonged duration of IFX therapy,without combination of immune-suppressors and with increased baseline body mass index (BMI) were the risk factors of acute infusion reactions.Prolonged duration of IFX therapy and with low baseline albumin level were the risk factors of infections.Conclusions IFX is generally safe as the treatment for CD patients,and its adverse effects can be clinically controlled.Screening before therapy and monitoring during therapy may reduce the risks of adverse effects.

S4358 Infliximab-Induced Autoimmune Hepatitis Progressing to Acute Liver Failure in a Patient With Ankylosing Spondylitis and Rheumatoid Arthritis

S4674 A Rare Case of Infliximab Induced Autoimmune Hepatitis

Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids

Efficacy and safety of infliximab in patients with autoimmune hepatitis

Drug-induced liver injury with autoimmune features secondary to infliximab for ulcerative colitis

S4403 A Case of Ibuprofen Induced Autoimmune Hepatitis Resulting in Acute on Chronic Liver Failure

S3847 Unexpected Complications of Infliximab: A Rare Case of Drug-Induced AIH-PBC Overlap in Crohn's Disease

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

Safety Of Infliximab Therapy In Rheumatoid Arthritis Patients With Previous Exposure To Hepatitis B Virus

Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review

A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease

P-030 Infliximab and Tuberculosis Infection

Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

Infliximab-induced reversible liver injury in a psoriatic patient

S3834 A Rare Complication: Tofacitinib-Induced Autoimmune Hemolytic Anemia in Ulcerative Colitis

Clinical characteristics and treatment outcomes of acute severe autoimmune hepatitis

Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview

Safety of Infliximab in Inflammatory Bowel Disease Patients With HBV Infection

Case report: Recombinant human type II tumour necrosis factor receptor-antibody fusion protein induced occult hepatitis B virus reactivation leading to liver failure

Certolizumab-Induced Liver Injury in Ankylosing Spondylitis: A Case Report and Causality Assessment

Synchronous Presentation of Autoimmune Hepatitis and Multiple Myeloma